Clincosm LogoSign in Get a demo

cml

Showing 1 - 20 of 20
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CML Trial in Tempe (Imatinib Mesylate, IkT-001Pro)

Recruiting
  • CML
  • Tempe, Arizona
    Celerion
Nov 21, 2022

Outcomes of Tyrosine Kinase Inhibitor(TKI)Stopping in Chronic

Recruiting
  • Folate
  • +2 more
    • Nantong, China
      Affliated Hospital of Nantong University
    Dec 13, 2021

    CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib

    Terminated
    Has Results
    • CML
    • +2 more
    • Las Vegas, Nevada
    • +2 more
    Apr 28, 2021

    CML, Imatinib Trial in Seoul (high-dose imatinib)

    Completed
    • CML
    • Imatinib
    • high-dose imatinib
    • Seoul, Korea, Republic of
      Novartis Investigational Site
    Mar 9, 2021

    Care Needs in CML and GIST Receiving Oral Targeted Therapy

    Completed
    • CML
    • GIST
      • Taipei, Taiwan
        National Taiwan University Hosptial
      Aug 7, 2020

      CML Trial in Brussels (200 Mg capsules of bosutinib in Water solution, bosunitib sorbitol, Bosutinib Mannitol)

      Completed
      • CML
      • 200 Mg capsules of bosutinib in Water solution
      • +13 more
      • Brussels, Belgium
        Pfizer Clinical Research Unit
      Jul 8, 2020

      ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (Rapamycin + high dose etoposide and cytarabine)

      Terminated
      • ALL
      • +3 more
      • Rapamycin + high dose etoposide and cytarabine
      • Philadelphia, Pennsylvania
        University of Pennsylvania Abramson Cancer Center
      Apr 15, 2020

      CML Trial in United States (nilotinib)

      Completed
      Has Results
      • CML
      • Birmingham, Alabama
      • +53 more
      Feb 25, 2020

      Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia Trial run by the NCI (Stem cell transplantation)

      Completed
      • Hodgkin Lymphoma
      • +8 more
      • Stem cell transplantation
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Dec 13, 2019

      Myeloid Leukemias, AML, Leukemia Trial in Philadelphia (Rapamycin, Mitoxantrone, Etoposide, Cytarabine, Rapamycin + MEC)

      Completed
      • Myeloid Leukemias
      • +3 more
      • Rapamycin, Mitoxantrone, Etoposide, Cytarabine
      • Rapamycin + MEC
      • Philadelphia, Pennsylvania
        University of Pennsylvania Abramson Cancer Center
      Jul 10, 2019

      CML, Nilotinib, Imatinib Resistant Trial in Seoul (nilotinib)

      Completed
      • CML
      • +3 more
      • Seoul, Korea, Republic of
        St. Mary hospital, Catholic medical center
      Feb 24, 2017

      CML, AML, MDS Trial in Philadelphia (Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm)

      Completed
      • CML
      • +6 more
      • Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells
      • Observation Arm
      • Philadelphia, Pennsylvania
        University of Pennsylvania
      Aug 17, 2016

      Leukemia, AML, MDS Trial in Houston (Cytarabine, Fludarabine)

      Completed
      Has Results
      • Leukemia
      • +3 more
      • Houston, Texas
        UT MD Anderson Cancer Center
      Feb 17, 2016

      Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Blast-phase Chronic Myelogenous Leukemia Trial in Tampa, Baltimore, Durham

      Completed
      • Acute Myeloid Leukemia
      • +5 more
      • STA-9090 (ganetespib)
      • Tampa, Florida
      • +2 more
      Sep 17, 2014

      AML, CML, MDS Trial in Boston, New York, San Antonio (STA-9090 (ganetespib))

      Completed
      • AML
      • +3 more
      • STA-9090 (ganetespib)
      • Boston, Massachusetts
      • +2 more
      Sep 17, 2014

      Unrelated Stem Cell Transplantation for Hematopoietic Disorders

      Completed
      • CML
      • +5 more
        • San Francisco, California
          University of California San Francisco
        Aug 1, 2013

        CML Trial in Petah tikva (Treatment modification based on molecular response at 3 months)

        Unknown status
        • CML
        • Treatment modification based on molecular response at 3 months
        • Petah tikva, Israel
          Rabin Medical Center
        Jan 7, 2013

        AML, CML, MDS Trial in New York (CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107))

        Completed
        • AML
        • +2 more
        • CYT107 - Recombinant glycosylated human interleukin 7.
        • rhIL-7 (CYT107)
        • New York, New York
          Memorial Sloan-Kettering Cancer Institute
        Jul 25, 2012

        Hematologic Malignancy, AML, ALL Trial in Boston (CD+8 T cell depletion)

        Completed
        • Hematologic Malignancy
        • +6 more
        • CD+8 T cell depletion
        • Boston, Massachusetts
        • +1 more
        Mar 15, 2012

        AML, MDS, ALL Trial in Seoul (fludarabine phosphate, busulfan)

        Unknown status
        • AML
        • +4 more
        • fludarabine phosphate, busulfan
        • Seoul, Korea, Republic of
          Dong Hwan Kim
        Dec 29, 2008